Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06732245
Registration number
NCT06732245
Ethics application status
Date submitted
9/12/2024
Date registered
13/12/2024
Date last updated
25/03/2025
Titles & IDs
Public title
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
Query!
Scientific title
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women
Query!
Secondary ID [1]
0
0
NA-931-200
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Obesity and Overweight
0
0
Query!
Condition category
Condition code
Diet and Nutrition
0
0
0
0
Query!
Obesity
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - NA-931
Treatment: Drugs - Tirzepatide
Treatment: Drugs - Tirzepatide
Treatment: Drugs - NA-931
Treatment: Drugs - NA-931
Treatment: Drugs - NA-931
Treatment: Drugs - NA-931 150 mg + no Tirzepatide
Treatment: Drugs - NA-931
Treatment: Drugs - NA-931
Placebo comparator: Placebo Comparator: Placebo - Placebo Comparator: Placebo to oral NA-931 120 mg daily + no Tirzepatide Participants will receive oral placebo at baseline and at Weeks 4, 12, and 24, 36, and 48 during the core treatment period and will switch during the extension period to receive NA-931 60 mg daily at Weeks 60 and 72.
Placebo comparator: Placebo + Tirzepatide 5 mg - Other: Placebo + Tirzepatide 5 mg Participants will receive oral placebo at baseline and at Weeks 4, 12, and 24, 36, and 48, and s.c. Tirzepatide 5 mg weekly per the dose escalation schedule.
Placebo comparator: Placebo + Tirzepatide 10 mg - Placebo + Tirzepatide 10 mg Participants will receive oral placebo at baseline and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 10 mg weekly per the dose escalation schedule.
Experimental: NA-931 60mg to NA-931 150 mg + no Tirzepatide - Experimental: NA-931 60mg to NA-931 150 mg + no Tirzepatide Participants will receive oral NA-931 60 mg at baseline and at Weeks 4, 12, and 24, 36, and 48 during the core treatment period and will switch during the extension period to receive NA-931 60 mg at Weeks 60 and 72.
Active comparator: NA-931 60 mg + Tirzepatide 5 mg - NA-931 60 mg + Tirzepatide 5 mg Participants will receive oral NA-931 60 mg at baseline and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 5 mg weekly per the dose escalation schedule.
Active comparator: NA-931 120 mg + Tirzepatide 5 mg - NA-931 120 mg + Tirzepatide 5 mg Participants will receive oral NA-931 60 mg at baseline and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 5 mg weekly per the dose escalation schedule.
Experimental: NA-931 150 mg + no Tirzepatide - Experimental: NA-931 150 mg + no Tirzepatide Participants will receive oral NA-931 150 mg at baseline and at Weeks 4, 12, 24, 36 and 48
Active comparator: NA-931 150 mg + Tirzepatide 2.5 mg - NA-931 150 mg + Tirzepatide 2.5 mg Participants will receive oral NA-931 150 mg at baseline, and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 2.5 mg weekly per the dose escalation schedule.
Active comparator: NA-931 150 mg + Tirzepatide 5 mg - NA-931 150 mg + Tirzepatide 5 mg Participants will receive oral NA-931 150mg at baseline and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 5 mg per the dose escalation schedule.
Treatment: Drugs: NA-931
NA-931 (oral, daily), a quadruple receptor agonist
Tirzepatide (Zepbound) placebo
Treatment: Drugs: Tirzepatide
Tirzepatide (s.c. weekly)
* Glucagon-like peptide-1 (GLP-1) receptor agonist
* Other Names:
* Mounjaro
* Zepbound NA-931 Placebo (oral, daily)
Treatment: Drugs: Tirzepatide
Tirzepatide (s.c. weekly), a Glucagon-like peptide-1 (GLP-1) receptor agonist
• Other Names:
* Mounjaro
* Zepbound
NA-931 Placebo (oral, daily)
Treatment: Drugs: NA-931
NA-931, an oral, daily
• A quadruple receptor agonist
Treatment: Drugs: NA-931
NA-931 (oral, daily), a quadruple receptor agonist
Tirzepatide (s.c. weekly)
* Glucagon-like peptide-1 (GLP-1) receptor agonist
* Other Names:
* Mounjaro
* Zepbound
Treatment: Drugs: NA-931
NA-931 (oral daily), a quadruple receptor agonist
Tirzepatide (s.c. weekly)
* Glucagon-like peptide-1 (GLP-1) receptor agonist
* Other Names:
* Mounjaro
* Zepbound
Treatment: Drugs: NA-931 150 mg + no Tirzepatide
NA-931 150 mg + no Tirzepatide
Treatment: Drugs: NA-931
NA-931 (oral, daily), a quadruple receptor agonist
Tirzepatide (s.c. weekly)
* Glucagon-like peptide-1 (GLP-1) receptor agonist
* Other Names:
* Mounjaro
* Zepbound
Treatment: Drugs: NA-931
NA-931 (oral, daily), a quadruple receptor agonist
Tirzepatide (s.c. weekly)
* Glucagon-like peptide-1 (GLP-1) receptor agonist
* Other Names:
* Mounjaro
* Zepbound
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change from baseline in body weight at 48 weeks
Query!
Assessment method [1]
0
0
Change in total body weight will be measured from baseline to 48 weeks
Query!
Timepoint [1]
0
0
48 weeks
Query!
Secondary outcome [1]
0
0
Change from baseline in waist circumference (cm) at 48 weeks
Query!
Assessment method [1]
0
0
Waist circumference will be measured in standing position with a non-stretchable measuring tape and to the nearest 0.1 centimeter (cm).
Query!
Timepoint [1]
0
0
48 weeks
Query!
Secondary outcome [2]
0
0
Change from baseline at 48 weeks in total body fat mass in kilograms (kg)
Query!
Assessment method [2]
0
0
Fat mass will be obtained by dual-energy x-ray absorptiometry (DXA) Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition.
Query!
Timepoint [2]
0
0
48 weeks
Query!
Secondary outcome [3]
0
0
Change from baseline at 48 weeks in percent body fat
Query!
Assessment method [3]
0
0
Percent body fat will be obtained by dual-energy x-ray absorptiometry (DXA) Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition.
Query!
Timepoint [3]
0
0
48 weeks
Query!
Secondary outcome [4]
0
0
Change from baseline at 48 weeks in visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT) and trunk fat mass by dual-energy x-ray absorptiometry (DXA)
Query!
Assessment method [4]
0
0
Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition.
Query!
Timepoint [4]
0
0
48 weeks
Query!
Secondary outcome [5]
0
0
Proportion of participants at 48 weeks with change in waist circumference = 5 cm
Query!
Assessment method [5]
0
0
Waist circumference will be measured in standing position with a non-stretchable measuring tape and to the nearest 0.1 centimeter (cm).
Query!
Timepoint [5]
0
0
48 weeks
Query!
Secondary outcome [6]
0
0
Proportion of participants at 48 weeks with change in Body weight = 5%, = 10% and =15%
Query!
Assessment method [6]
0
0
Body weight will be measured in kilograms (kg) to the nearest 0.1 kg.
Query!
Timepoint [6]
0
0
48 weeks
Query!
Secondary outcome [7]
0
0
Proportion of participants at 48 weeks with change in Fat mass = 5% = 10% = 15% by Dual energy X-ray absorptiometry (DXA)
Query!
Assessment method [7]
0
0
Dual energy X-ray absorptiometry (DXA) will be used to assess the changes in body composition.
Query!
Timepoint [7]
0
0
48 weeks
Query!
Secondary outcome [8]
0
0
Proportion of participants at 48 weeks with change in Fat mass = 10% with <5% decrease (or and increase) in lean mass by Dual energy X-ray absorptiometry (DXA)
Query!
Assessment method [8]
0
0
Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition.
Query!
Timepoint [8]
0
0
48 weeks
Query!
Secondary outcome [9]
0
0
Percentage of weight loss due to fat mass or lean mass at 48 weeks by dual-energy x-ray absorptiometry (DXA)
Query!
Assessment method [9]
0
0
Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition
Query!
Timepoint [9]
0
0
48 weeks
Query!
Secondary outcome [10]
0
0
Change from baseline at 48 weeks in fat mass (kg and %) by bioelectrical impedance analysis (BIA)
Query!
Assessment method [10]
0
0
Bioelectrical impedance analysis (BIA) is a widely used method for estimating body composition.
Query!
Timepoint [10]
0
0
48 weeks
Query!
Secondary outcome [11]
0
0
Change from baseline at 48 weeks in lean mass (kg and %) and appendicular lean mass by dual-energy x-ray absorptiometry (DXA)
Query!
Assessment method [11]
0
0
Dual-energy x-ray absorptiometry (DXA) will be used to assess changes in body composition.
Query!
Timepoint [11]
0
0
48 weeks
Query!
Secondary outcome [12]
0
0
Change from baseline at 48 weeks in lean mass (kg) by bioelectrical impedance analysis (BIA)
Query!
Assessment method [12]
0
0
Bioelectrical impedance analysis (BIA) is a widely used method for estimating body composition.
Query!
Timepoint [12]
0
0
48 weeks
Query!
Secondary outcome [13]
0
0
Safety and tolerability measurements throughout 48 weeks by TEAEs [safety labs, vital signs]
Query!
Assessment method [13]
0
0
Incidence and severity of treatment emergent adverse events (TEAEs)
Query!
Timepoint [13]
0
0
48 weeks
Query!
Secondary outcome [14]
0
0
Proportion of Participants with change from baseline in Body Mass Index (BMI) categories at 48 weeks
Query!
Assessment method [14]
0
0
BMI categories: (i) Healthy weight: 18.5 kg/m2 to 24.9 kg/m2 (ii) Overweight: 25 kg/m2 to 29.9 kg/m2 (iii) Obesity class 1: 30 kg/m2 to 34.9 kg/m2 (iv) Obesity class II: 35 kg/m2 to 39.9 kg/m2 (v) Obesity class III: = 40 kg/m2
Query!
Timepoint [14]
0
0
48 weeks
Query!
Secondary outcome [15]
0
0
Proportion of Participants with change from baseline in waist-to-height ratio (WHtR ratio) categories at 48 weeks
Query!
Assessment method [15]
0
0
Waist-to-height ratio WHtR ratio categories: \<0.5; 0.5-0.59; =0.6.
Query!
Timepoint [15]
0
0
48 weeks
Query!
Secondary outcome [16]
0
0
Change from baseline in HbA1c (mmol/mol) at 48 weeks
Query!
Assessment method [16]
0
0
To assess treatment effects on glucose metabolism and HbA1c.
Query!
Timepoint [16]
0
0
48 weeks
Query!
Secondary outcome [17]
0
0
Change from baseline at 48 weeks in Quality of Life Short Form 36 (SF-36) survey
Query!
Assessment method [17]
0
0
Change from baseline at 48 weeks in Quality of Life Short Form 36 (SF-36) survey. To assess a subject's overall health related quality of life, as well as the physical functioning score. SF- 36 scores range from 0 (worst) to 100 (best).
Query!
Timepoint [17]
0
0
48 weeks
Query!
Secondary outcome [18]
0
0
Change from Baseline at 48 weeks in Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite)
Query!
Assessment method [18]
0
0
Change from baseline in IWQOL-Lite CT. IWQOL-Lite CT is a 20-item modified survey instrument that is used to quantitatively assess an individual's perception of how their weight affects their day- to-day life, as well as the physical function score. Scores range from 0 (worst) to 100 (best).
Query!
Timepoint [18]
0
0
48 weeks
Query!
Eligibility
Key inclusion criteria
* A written informed consent must be obtained before any study-related assessments are performed.
* Men and women between 18 and 80 years, inclusive; women of child-bearing potential (defined as those who are not post-menopausal or post-surgical sterilization) must meet both of the following criteria:
* Two negative pregnancy tests (at screening and at randomization, prior to dosing)
* Use of intrauterine device, from at least 3 months before the baseline visit through at least 4 months after the last dose of NA-931/placebo oral, and an additional contraceptive (barrier) method from screening through at least 4 months after the last dose of NA-931/placebo oral.
* Body mass index (BMI) = 30 or BMI = 27 with one or more obesity-associated comorbidities (e.g., hypertension, insulin resistance, sleep apnea, or dyslipidemia)
* Stable body weight (± 5 kg) within 90 days of screening, and body weight <150 kg
* Have a history of at least one self-reported unsuccessful behavioral effort to lose body weight
* Able to communicate well with the Investigator, comply with the study requirements and adhere to the diet and activity programs for the study duration
Query!
Minimum age
19
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* • History of, or known hypersensitivity to, monoclonal antibody drugs or a contraindication to Tirzepatide (Zepbound® or Mounjaro®)
* Use of other investigational drugs at the time of enrollment or within 30 days or 5 half-lives of enrollment, whichever is longer, or longer if required by local regulations
* Treatment with any medication for the indication of obesity within the past 30 days before screening
* Diagnosis of diabetes requiring current use of any antidiabetic drug or HbA1c = 6.5% Note: Metabolic syndrome is not an exclusion, even if managed with an anti-diabetic drug such as metformin or an SGLT2 inhibitor. A diagnosis of prediabetes or impaired glucose tolerance managed exclusively with non-pharmacologic approaches (e.g., diet and exercise) is not an exclusion.
* Any chronic infections likely to interfere with study conduct or interpretation such as hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV). History of hepatitis A or hepatitis C successfully treated is not exclusionary. Active COVID-19 infection.
* Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing, or longer if required by local regulation, or plasma donation (> 250 mL) within 14 days prior to the first dose
* Any disorder, unwillingness, or inability not covered by any of the other exclusion criteria, which in the Investigator's opinion, might jeopardize the participant's safety or compliance with the protocol
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Factorial
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
15/03/2025
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
15/12/2026
Query!
Actual
Query!
Sample size
Target
224
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Biomed Research Unit-NSW-2100-109 - Brookvale
Query!
Recruitment hospital [2]
0
0
Biomed Research Unit-NSW-2065-110 - Saint Leonards,
Query!
Recruitment hospital [3]
0
0
, Australia, 4101 Biomed Research Unit-NSW-4101-111 - South Brisbane,
Query!
Recruitment hospital [4]
0
0
Biomed Research Unit-VIC-3124-112 - Camberwell,
Query!
Recruitment hospital [5]
0
0
, Victoria, Australia, 3084 Biomed Research Unit-VIC-3084-113 - Heidelberg West
Query!
Recruitment postcode(s) [1]
0
0
2100 - Brookvale
Query!
Recruitment postcode(s) [2]
0
0
2065 - Saint Leonards,
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane,
Query!
Recruitment postcode(s) [4]
0
0
3124 - Camberwell,
Query!
Recruitment postcode(s) [5]
0
0
3084 - Heidelberg West
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New York
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Texas
Query!
Country [5]
0
0
New Zealand
Query!
State/province [5]
0
0
Auckland
Query!
Country [6]
0
0
New Zealand
Query!
State/province [6]
0
0
Wellington
Query!
Country [7]
0
0
New Zealand
Query!
State/province [7]
0
0
Hamilton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Biomed Industries, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Bioneurals Ltd
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
Query!
Trial website
https://clinicaltrials.gov/study/NCT06732245
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Lloyd Tran, PhD
Query!
Address
0
0
Biomed Industries, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Lloyd Tran, PhD
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-800-824-5135
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06732245
Download to PDF